FDA Approves Medication To Treat Bipolar Disorder And Schizophrenia

Reuters (9/18, Nathan) reports that the Food and Drug Administration approved Allergan Plc’s new antipsychotic drug, Vraylar (cariprazine), to treat patients with bipolar disorder and schizophrenia. The drug has a boxed warning of increased risk of death in older patients who have dementia-related psychosis.

MedPage Today (9/18, Fiore) reports that the drug “is a partial agonist of the dopamine D3 and D2 and serotonin 5-HT1A receptors,” is “an antagonist of the serotonin 5-HT2B and 5-HT2A receptors, and it also binds to histamine H1 receptors.”

Related Links:

— “Allergan gets FDA nod for new antipsychotic,” Vidya L Nathan, Reuters, September 17, 2015.

Posted in In The News.